Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 4Phase 3 3Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 6Carcinoma, Hepatocellular 3Multiple Myeloma 2Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Kidney Neoplasms 1Kidney Diseases 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × cabozantinib × Clear all
NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
49 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡